643 related articles for article (PubMed ID: 11694787)
1. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
2. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
3. First-line Herceptin monotherapy in metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
[TBL] [Abstract][Full Text] [Related]
4. Dose scheduling--Herceptin.
Leyland-Jones B
Oncology; 2001; 61 Suppl 2():31-6. PubMed ID: 11694785
[TBL] [Abstract][Full Text] [Related]
5. Role of Herceptin in primary breast cancer: views from North America and Europe.
Leyland-Jones B; Smith I
Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
[TBL] [Abstract][Full Text] [Related]
6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
8. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
Ficorella C
Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
[No Abstract] [Full Text] [Related]
9. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
10. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
Meden H; Beneke A; Hesse T; Novophashenny I; Wischnewsky M
Anticancer Res; 2001; 21(2B):1301-5. PubMed ID: 11396203
[TBL] [Abstract][Full Text] [Related]
11. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
Gori S; Colozza M; Mosconi AM; Franceschi E; Basurto C; Cherubini R; Sidoni A; Rulli A; Bisacci C; De Angelis V; Crinò L; Tonato M
Br J Cancer; 2004 Jan; 90(1):36-40. PubMed ID: 14710203
[TBL] [Abstract][Full Text] [Related]
13. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Burris HA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
[TBL] [Abstract][Full Text] [Related]
15. Trials of new combinations of Herceptin in metastatic breast cancer.
Thomssen C
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S19-25. PubMed ID: 11989523
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
17. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Merlin JL; Barberi-Heyob M; Bachmann N
Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
[TBL] [Abstract][Full Text] [Related]
18. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E
Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
[No Abstract] [Full Text] [Related]
19. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.
Burstein HJ; Keshaviah A; Baron AD; Hart RD; Lambert-Falls R; Marcom PK; Gelman R; Winer EP
Cancer; 2007 Sep; 110(5):965-72. PubMed ID: 17614302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
